CoChat

Methods and validity indicators for measuring adherence to statins in secondary cardiovascular prevention: a systematic review

López-Pineda, Adriana, Martinez-Muñoz, María, Nouni-García, Rauf, Esquerdo-Arroyo, Amanda, Carbonell-Soliva, Álvaro, Ramirez-Familia, Elizabeth, Tomás-Rodríguez, Mª Isabel, Quesada, Jose A., C, Concepción Carratalá-Munuera, Gil-Guillén, Vicente F. · 2025 · Systematic Reviews

Published version of a preprint

Cited by 11

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13643-025-02853-9

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 109

  1. Bansilal S, Castellano JM, Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol. 2015;201(Suppl):1. https://doi.org/10.1016/S0167-5273(15)31026-3. PMID: 26747389. · DOI · Paper page
  2. Perel P, Avezum A, Huffman M, Pais P, Rodgers A, Vedanthan R, Wood D, Yusuf S. Reducing premature cardiovascular morbidity and mortality in people with atherosclerotic vascular disease: the World Heart Federation roadmap for secondary prevention of cardiovascular disease. Glob Heart. 2015;10(2):99–110. https://doi.org/10.1016/j.gheart.2015.04.003. Erratum.In:GlobHeart.2015Sep;10(3):225 PMID: 26213297. · DOI · Paper page
  3. Laranjo L, Lanas F, Sun MC, Chen DA, Hynes L, Imran TF, et al. World Heart Federation roadmap for secondary prevention of cardiovascular disease: 2023 update. Glob Heart. 2024;19(1): 8. https://doi.org/10.5334/gh.1278. · DOI
  4. López-Sendón J, González-Juanatey JR, Pinto F, Cuenca Castillo J, Badimón L, Dalmau R, et al. Indicadores de calidad en cardiología. Principales indicadores para medir la calidad de los resultados e indicadores de práctica asistencial. INCARDIO: Declaración de posicionamiento de consenso de SEC/SECTCV. Rev Esp Cardiol. 2015;68:976-995.e10. · DOI
  5. Francula-Zaninovic S, Nola IA. Management of measurable variable cardiovascular disease risk factors. Curr Cardiol Rev. 2018;14(3):153–63. https://doi.org/10.2174/1573403X14666180222102312. PMID:29473518;PMCID:PMC6131408. · DOI · Paper page
  6. Mangoni AA, Jackson SH. The implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular prevention. Br J Clin Pharmacol. 2006;61(5):494–501. https://doi.org/10.1111/j.1365-2125.2006.02609.x. PMID: 16669841; PMCID: PMC1885067. · DOI
  7. Gackowski M, Jasińska-Stroschein M, Osmałek T, Waszyk-Nowaczyk M. Innovative approaches to enhance and measure medication adherence in chronic disease management: a review. Med Sci Monit. 2024;16(30):e944605. https://doi.org/10.12659/MSM.944605. PMID:39012851;PMCID:PMC11302205. · DOI
  8. Dilla T, Valladares A, Lizán L, Sacristán JA. Adherencia y persistencia terapéutica: causas, consecuencias y estrategias de mejora. Aten Primaria. 2009;41(6):342–8. https://doi.org/10.1016/j.aprim.2008.09.031. · DOI
  9. Lopes N, Zanini AC, Casella-Filho A, Chagas AC. Metabolic syndrome patient compliance with drug treatment. Clinics (Sao Paulo). 2008;63(5):573–80. https://doi.org/10.1590/s1807-59322008000500002. PMID:18925314;PMCID:PMC2664712. · DOI
  10. Ramandi A, George J, Merat S, Jafari E, Sharafkhah M, Radmard AR, Nateghi Baygi A, Delavari A, Mohammadi Z, Poustchi H, Malekzadeh R. Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial. Hepatol Int. 2023;17(4):882–8. https://doi.org/10.1007/s12072-023-10542-9. Epub 2023 May 25 PMID: 37227560. · DOI
  11. Conthe P, Márquez Contreras E, Aliaga Pérez A, Barragán García B, Fernández de Cano Martín MN, González Jurado M, et al. Treatment compliance in chronic illness: current situation and future perspectives. Rev Clin Esp (Barc). 2014;214(6):336–44. https://doi.org/10.1016/j.rce.2014.03.008. · DOI
  12. Gagnon MD, Waltermaurer E, Martin A, Friedenson C, Gayle E, Hauser DL. Patient beliefs have a greater impact than barriers on medication adherence in a community health center. J Am Board Fam Med. 2017;30(3):331–6. https://doi.org/10.3122/jabfm.2017.03.160129. · DOI
  13. Orozco-Beltrán D, Carratalá-Munuera C, Gil-Guillén V. Mejorar la adherencia: una de las acciones más eficientes para aumentar la supervivencia de los pacientes en prevención secundaria. Rev Esp Cardiol Supl. 2015;15(E):12–8. https://doi.org/10.1016/s1131-3587(16)30004-. · doi:10.1016/s1131-3587(16)30004-
  14. López-Romero LA, Romero-Guevara SL, Parra DI, Rojas-Sánchez LZ. Adherencia al tratamiento: concepto y medición. Rev Hacia Promoción Salud. 2016;21: 10. https://doi.org/10.17151/hpsal.2016.21.1.10. · DOI
  15. Pagès-Puigdemont N, Valverde-Merino MI. Métodos para medir la adherencia terapéutica. Ars Pharm. 2018;59(3):163–72. https://doi.org/10.30827/ars.v59i3.7387. · DOI
  16. Sackett DL, Haynes RB, Gibson ES, et al. Patient compliance with antihypertensive regimens. Patient Couns Health Educ. 1978;1:18–21. · DOI
  17. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348–54. https://doi.org/10.1111/j.1751-7176.2008.07572.x. Retraction.In:JClinHypertens(Greenwich).2023Sep;25(9):889-890.PMID:18453793;PMCID:PMC2562622. · DOI · Paper page
  18. Ali M, Kerr AJ, Lee M, Chan DZL. What is the statin possession ratio cut-off which identifies those at increased risk following acute coronary syndrome (ANZACS-QI 68)? Heart Lung Circ. 2023;32(4):487–96. https://doi.org/10.1016/j.hlc.2022.11.012. PMID: 36641263. · DOI
  19. Allonen J, Nieminen MS, Lokki M, Parkkonen O, Vaara S, Perola M, et al. Mortality rate increases steeply with nonadherence to statin therapy in patients with acute coronary syndrome. Clin Cardiol. 2012; 35(11). https://doi.org/10.1002/clc.22056. PMID: 22961648; PMCID: PMC6652510. · DOI
  20. Alsabbagh MW, Eurich D, Lix LM, Wilson TW, Blackburn DF. Does the association between adherence to statin medications and mortality depend on measurement approach? A retrospective cohort study. BMC Med Res Methodol. 2017;17(1):66. https://doi.org/10.1186/s12874-017-0339-z. PMID:28427340;PMCID:PMC5397806. · DOI
  21. Martinez-Perez P, Orozco-Beltrán D, Pomares-Gomez F, Hernández-Rizo JL, Borras-Gallen A, Gil-Guillen VF, et al. Validation and psychometric properties of the 8-item Morisky Medication Adherence Scale (MMAS-8) in type 2 diabetes patients in Spain. Aten Primaria. 2021;53(2):101942. https://doi.org/10.1016/j.aprim.2020.09.007. PMID:33508739;PMCID:PMC7844132. · DOI
  22. Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015: 217047. · DOI · Paper page
  23. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19(4):539–49. https://doi.org/10.1007/s11136-010-9606-8. PMID:20169472;PMCID:PMC2852520. · DOI · Paper page
  24. Al-Khadra S, Meisinger C, Amann U, Holle R, Kuch B, Seidl H, et al. Secondary prevention medication after myocardial infarction: persistence in elderly people over the course of 1 year. Drugs Aging. 2014;31(7):513–25. https://doi.org/10.1007/s40266-014-0189-x. PMID: 24919974. · DOI
  25. Bell KJ, Kirby A, Hayen A, Irwig L, Glasziou P. Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. BMJ. 2011;21:342. https://doi.org/10.1136/bmj.d12. PMID: 21257657. · DOI
  26. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy. 2005;25(8):1035–43. https://doi.org/10.1592/phco.2005.25.8.1035. PMID: 16207093. · DOI · Paper page
  27. Booth JN 3rd, Colantonio LD, Chen L, Rosenson RS, Monda KL, Safford MM, et al. Statin discontinuation, reinitiation, and persistence patterns among Medicare beneficiaries after myocardial infarction: a cohort study. Circ Cardiovasc Qual Outcomes. 2017;10(10). https://doi.org/10.1161/CIRCOUTCOMES.117.003626. PMID: 29021332. · DOI
  28. Brogaard HV, Køhn MG, Berget OS, Hansen HS, Gerke O, Mickley H, et al. Significant improvement in statin adherence and cholesterol levels after acute myocardial infarction. Dan Med J. 2012;59(9):A4509 PMID: 22951203.
  29. Brown R, Lewsey J, Wild S, Logue J, Welsh P. Associations of statin adherence and lipid targets with adverse outcomes in myocardial infarction survivors: a retrospective cohort study. BMJ Open. 2021 Sep 27;11(9). https://doi.org/10.1136/bmjopen-2021-054893. PMID: 34580105; PMCID: PMC8477332. · DOI
  30. Carey IM, DeWilde S, Shah SM, Harris T, Whincup PH, Cook DG. Statin use after first myocardial infarction in UK men and women from 1997 to 2006: who started and who continued treatment? Nutr Metab Cardiovasc Dis. 2012;22(5):400–8. https://doi.org/10.1016/j.numecd.2010.09.010. PMID: 21194912. · DOI
  31. Chan V, Cooke CE. Pharmacotherapy after myocardial infarction: disease management versus usual care. Am J Manag Care. 2008;14(6):352–8 PMID: 18554073.
  32. Chen PS, Cheng CL, Kao Yang YH, Li YH. Statin adherence after ischemic stroke or transient ischemic attack is associated with clinical outcome. Circ J. 2016;80(3):731–7. https://doi.org/10.1253/circj.CJ-15-0753. PMID: 26742588. · DOI
  33. Chen ST, Huang ST, Shau WY, Lai CL, Li JZ, Fung S, Tse VC, Lai MS. Long-term statin adherence in patients after hospital discharge for new onset of atherosclerotic cardiovascular disease: a population-based study of real-world prescriptions in Taiwan. BMC Cardiovasc Disord. 2019;19(1):62. https://doi.org/10.1186/s12872-019-1032-4. PMID:30876393;PMCID:PMC6420763. · DOI
  34. Chi MD, Vansomphone SS, Liu IL, Cheetham C, Green KR, Scott RD, Reynolds K. Adherence to statins and LDL-cholesterol goal attainment. Am J Manag Care. 2014;20(4). PMID: 24884955.
  35. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088–97. https://doi.org/10.1056/NEJMsa1107913. PMID: 22080794. · DOI · Paper page
  36. Chow CK, Klimis H, Thiagalingam A, Redfern J, Hillis GS, Brieger D, et al. Text messages to improve medication adherence and secondary prevention after acute coronary syndrome: the TEXTMEDS randomized clinical trial. Circulation. 2022;145(19):1443–55. https://doi.org/10.1161/CIRCULATIONAHA.121.056161. PMID: 35533220. · DOI
  37. Chung PW, Yoon BW, Lee YB, Shin BS, Kim HY, Park JH, et al. Medication adherence of statin users after acute ischemic stroke. Eur Neurol. 2018;80(1–2):106–14. https://doi.org/10.1159/000493530. PMID: 30347393. · DOI
  38. Coberley C, Morrow G, McGinnis M, Wells A, Coberley S, Orr P, et al. Increased adherence to cardiac standards of care during participation in cardiac disease management programs. Dis Manag. 2008;11(2):111–8. https://doi.org/10.1089/dis.2008.112725. · DOI
  39. Colantonio LD, Huang L, Monda KL, Bittner V, Serban MC, Taylor B, et al. Adherence to high-intensity statins following a myocardial infarction hospitalization among Medicare beneficiaries. JAMA Cardiol. 2017;2(8):890–5. https://doi.org/10.1001/jamacardio.2017.0911. PMID:28423147;PMCID:PMC5815081. · DOI · Paper page
  40. Cooke CE, Bresette JL, Khanna R. Statin use in American Indians and Alaska Natives with coronary artery disease. Am J Health Syst Pharm. 2006;63(18):1717–22. https://doi.org/10.2146/ajhp050517. PMID: 16960255. · DOI
  41. Di Martino M, Alagna M, Cappai G, Mataloni F, Lallo A, Perucci CA, Davoli M, Fusco D. Adherence to evidence-based drug therapies after myocardial infarction: is geographic variation related to hospital of discharge or primary care providers? A cross-classified multilevel design. BMJ Open. 2016;6(4):e010926. https://doi.org/10.1136/bmjopen-2015-010926. PMID:27044584;PMCID:PMC4823440. · DOI
  42. Fanaroff AC, Peterson ED, Kaltenbach LA, Cannon CP, Choudhry NK, Henry TD, et al. Association of a P2Y12 inhibitor copayment reduction intervention with persistence and adherence with other secondary prevention medications: a post hoc analysis of the ARTEMIS cluster-randomized clinical trial. JAMA Cardiol. 2020;5(1):38–46. https://doi.org/10.1001/jamacardio.2019.4408. PMID:31721978;PMCID:PMC6865296. · doi:10.1001/jamacardio.2019.4408
  43. Faridi KF, Peterson ED, McCoy LA, Thomas L, Enriquez J, Wang TY. Timing of first postdischarge follow-up and medication adherence after acute myocardial infarction. JAMA Cardiol. 2016;1(2):147–55. https://doi.org/10.1001/jamacardio.2016.0001. PMID: 27437885. · DOI
  44. Griffiths B, Lesosky M, Ntsekhe M. Self-reported use of evidence-based medicine and smoking cessation 6–9 months after acute coronary syndrome: a single-centre perspective. S Afr Med J. 2014;104(7):483–7. https://doi.org/10.7196/samj.7798. PMID: 25214049. · DOI
  45. Ho PM, Lambert-Kerzner A, Carey EP, Fahdi IE, Bryson CL, Melnyk SD, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Intern Med. 2014;174(2):186–93. https://doi.org/10.1001/jamainternmed.2013.12944. PMID: 24247275. · DOI · Paper page
  46. Hoang C, Kolenic G, Kline-Rogers E, Eagle KA, Erickson SR. Mapping geographic areas of high and low drug adherence in patients prescribed continuing treatment for acute coronary syndrome after discharge. Pharmacotherapy. 2011;31(10):927–33. https://doi.org/10.1592/phco.31.10.927. PMID: 21950639. · DOI
  47. Hudson M, Rahme E, Richard H, Pilote L. Comparison of measures of medication persistency using a prescription drug database. Am Heart J. 2007;153(1):59–65. https://doi.org/10.1016/j.ahj.2006.10.018. PMID: 17174638. · DOI
  48. Huynh T, Lecca P, Montigny M, Gagnon R, Eisenberg MJ, Lauzon C, et al. Ten-year statin adherence in survivors of ST-segment elevation myocardial infarction. J Popul Ther Clin Pharmacol. 2018;25(2). https://doi.org/10.22374/1710-6222.25.2.5. PMID: 30725543. · DOI
  49. Khunti K, Danese MD, Kutikova L, Catterick D, Sorio-Vilela F, Gleeson M, Kondapally Seshasai SR, Brownrigg J, Ray KK. Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and/or ezetimibe. JAMA Netw Open. 2018;1(8):e185554. https://doi.org/10.1001/jamanetworkopen.2018.5554. PMID:30646277;PMCID:PMC6324347. · DOI · Paper page
  50. Kirsch F, Becker C, Schramm A, Maier W, Leidl R. Patients with coronary artery disease after acute myocardial infarction: effects of continuous enrollment in a structured disease management program on adherence to guideline-recommended medication, healthcare expenditures, and survival. Eur J Health Econ. 2020;21(5):607–19. https://doi.org/10.1007/s10198-020-01158-z. · DOI
  51. Kocas C, Abaci O, Oktay V, Coskun U, Bostan C, Yildiz A, et al. Percutaneous coronary intervention vs. optimal medical therapy–the other side of the coin: medication adherence. J Clin Pharm Ther. 2013;38(6):476–9. https://doi.org/10.1111/jcpt.12091. PMID: 23992279. · DOI
  52. Korol S, Wsół A, Puchalska L, Reshetnik A. Medication adherence and its impact on the average life expectancy after ST-segment elevation myocardial infarction: the results of the Ukrainian STIMUL registry. Wiad Lek. 2022;75(3):563–9 PMID: 35522859. · doi:10.36740/wlek202203101
  53. Kristiansen O, Sverre E, Peersen K, Fagerland MW, Gjertsen E, Gullestad L, et al. The relationship between directly measured statin adherence, self-reported adherence measures, and cholesterol levels in patients with coronary heart disease. Atherosclerosis. 2021;336:23–9. https://doi.org/10.1016/j.atherosclerosis.2021.09.020. PMID: 34610521. · DOI
  54. Kulik A, Shrank WH, Levin R, Choudhry NK. Adherence to statin therapy in elderly patients after hospitalization for coronary revascularization. Am J Cardiol. 2011;107(10):1409–14. https://doi.org/10.1016/j.amjcard.2011.01.013. PMID: 21414595. · DOI
  55. Lee JK, Grace KA, Foster TG, Crawley MJ, Erowele GI, Sun HJ, et al. How should we measure medication adherence in clinical trials and practice? Ther Clin Risk Manag. 2007;3(4):685–90 PMID: 18472991; PMCID: PMC2374934.
  56. Liao YB, Lee M, Poppe KK, Kerr AJ, Stewart RAH. A risk model to predict statin non-adherence following an acute coronary syndrome. Heart Lung Circ. 2023;32(5):612–8. https://doi.org/10.1016/j.hlc.2023.01.015. PMID: 36933980. · DOI
  57. Librero J, Sanfélix-Gimeno G, Peiró S. Medication adherence patterns after hospitalization for coronary heart disease A population-based study using electronic records and group-based trajectory models. PLoS One. 2016;11(8):e0161381. https://doi.org/10.1371/journal.pone.0161381. PMID: 27551748; PMCID: PMC4995009. · DOI
  58. Lip GYH, Genaidy A, Jones B, Tran G, Estes C, Sloop S. Medication non-adherence patterns and profiles for patients with incident myocardial infarction: observations from a large multimorbid US population. Eur J Clin Invest. 2023;53(6). https://doi.org/10.1111/eci.13968. PMID: 36789887. · DOI
  59. Maddison R, Jiang Y, Stewart R, Scott T, Kerr A, Whittaker R, et al. An intervention to improve medication adherence in people with heart disease (Text4HeartII): randomized controlled trial. JMIR Mhealth Uhealth. 2021;9(6). https://doi.org/10.2196/24952. PMID: 34106081; PMCID: PMC8262599. · DOI
  60. McGinnis BD, Olson KL, Delate TM, Stolcpart RS. Statin adherence and mortality in patients enrolled in a secondary prevention program. Am J Manag Care. 2009;15(10):689–95 PMID: 19845421.
  61. Mechtouff L, Haesebaert J, Viprey M, Tainturier V, Termoz A, Porthault-Chatard S, David JS, Derex L, Nighoghossian N, Schott AM. Secondary prevention three and six years after stroke using the French National Insurance Healthcare System Database. Eur Neurol. 2018;79(5–6):272–80. https://doi.org/10.1159/000488450. Epub 2018 May 14 PMID: 29758555. · DOI
  62. Navar AM, Roe MT, White JA, Cannon CP, Lokhnygina Y, Newby LK, et al. Medication discontinuation in the IMPROVE-IT trial. Circ Cardiovasc Qual Outcomes. 2019;12(1). https://doi.org/10.1161/CIRCOUTCOMES.118.005041. PMID: 30630361; PMCID: PMC6541480. · DOI
  63. Padilla López A. Statin adherence and health outcomes after ST-elevation myocardial infarction: 1-year follow-up study. Rev Clin Esp (Barc). 2021;221(6):331–40. https://doi.org/10.1016/j.rceng.2020.04.012. PMID: 34059230. · DOI
  64. Park LG, Howie-Esquivel J, Chung ML, Dracup K. A text messaging intervention to promote medication adherence for patients with coronary heart disease: a randomized controlled trial. Patient Educ Couns. 2014;94(2):261–8. https://doi.org/10.1016/j.pec.2013.10.027. PMID: 24321403. · DOI · Paper page
  65. Phan DQ, Duan L, Lam B, Hekimian A, Wee D, Zadegan R, Lee MS. Statin adherence and mortality in patients aged 80 years and older after acute myocardial infarction. J Am Geriatr Soc. 2019;67(10):2045–9. https://doi.org/10.1111/jgs.16037. PMID: 31206603. · DOI
  66. Pietrzykowski Ł, Kasprzak M, Michalski P, Kosobucka A, Fabiszak T, Kubica A. Therapy discontinuation after myocardial infarction. J Clin Med. 2020;9(12):4109. https://doi.org/10.3390/jcm9124109. PMID:33352811;PMCID:PMC7766090. · doi:10.3390/jcm9124109
  67. Qvist I, Lindholt JS, Søgaard R, Lorentzen V, Hallas J, Frost L. Randomised trial of telephone counselling to improve participants’ adherence to prescribed drugs in a vascular screening trial. Basic Clin Pharmacol Toxicol. 2020;127(6):477–87. https://doi.org/10.1111/bcpt.13459. PMID: 32564482. · DOI
  68. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177–86. https://doi.org/10.1001/jama.297.2.177. PMID: 17213401. · DOI · Paper page
  69. Reddy A, Huseman TL, Canamucio A, Marcus SC, Asch DA, Volpp KG, Long JA. Patient and partner feedback reports to improve statin medication adherence: a randomized control trial. J Gen Intern Med. 2017;32(3):256–61. https://doi.org/10.1007/s11606-016-3858-0. PMID:27612487;PMCID:PMC5330995. · DOI
  70. Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019;4(3):206–13. https://doi.org/10.1001/jamacardio.2018.4936. PMID:30758506;PMCID:PMC6439552. · DOI · Paper page
  71. Schiele F, Quignot N, Khachatryan A, Gusto G, Villa G, Kahangire D, Chauny JV, Ricci L, Desamericq G. Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: five years of clinical follow-up from 164,565 post-myocardial infarction patients. Int J Cardiol. 2021;1(332):22–8. https://doi.org/10.1016/j.ijcard.2021.03.007. Epub 2021 Mar 8 PMID: 33705845. · DOI
  72. Schwalm JD, Ivers NM, Bouck Z, Taljaard M, Natarajan MK, Dolovich L, et al. Length of initial prescription at hospital discharge and long-term medication adherence for elderly, post-myocardial infarction patients: protocol for an interrupted time series study. JMIR Res Protoc. 2020;9(11). https://doi.org/10.2196/18981. PMID: 33146624; PMCID: PMC7673978. · DOI
  73. Shalev V, Goldshtein I, Halpern Y, Chodick G. Association between persistence with statin therapy and reduction in low-density lipoprotein cholesterol level: analysis of real-life data from community settings. Pharmacotherapy. 2014;34(1):1–8. https://doi.org/10.1002/phar.1326. PMID: 23836549. · DOI
  74. Shau WY, Lai CL, Huang ST, Chen ST, Li JZ, Fung S, Tse VC, Lai MS. Statin adherence and persistence on secondary prevention of cardiovascular disease in Taiwan. Heart Asia. 2019;11(2). https://doi.org/10.1136/heartasia-2018-011176. PMID: 31565075; PMCID: PMC6743447. · DOI
  75. Simonyi G. Lipidcsökkentő terápia és betegadherencia a MULTI GAP 2013 vizsgálat tükrében [Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial]. Orv Hetil. 2014;155(17):669–75. Hungarian. https://doi.org/10.1556/OH.2014.29905. PMID: 24755449. · DOI
  76. Sjölander M, Eriksson M, Glader EL. Inequalities in medication adherence to statin treatment after stroke: a nationwide observational study. Eur Stroke J. 2016;1(2):101–7. https://doi.org/10.1177/2396987316646026. PMID:31008271;PMCID:PMC6301226. · DOI
  77. Soldati S, Di Martino M, Castagno D, Davoli M, Fusco D. In-hospital myocardial infarction and adherence to evidence-based drug therapies: a real-world evaluation. BMJ Open. 2021;11(2):e042878. https://doi.org/10.1136/bmjopen-2020-042878. PMID:33550255;PMCID:PMC7925929. · DOI
  78. Souza Groia Veloso RC, Cruzeiro MGM, Dias BM, Reis AMM. Assessment of adherence to statin therapy in patients with coronary artery disease: comparison of three self-reporting measures. Eur. J Hosp Pharm. 2023;30(1):24–8. https://doi.org/10.1136/ejhpharm-2021-002725. PMID: 34031152; PMCID: PMC9811568. · DOI
  79. Stuart B, Davidoff A, Erten M, Gottlieb SS, Dai M, Shaffer T, et al. How Medicare Part D benefit phases affect adherence with evidence-based medications following acute myocardial infarction. Health Serv Res. 2013;48(6 Pt 1):1960–77. https://doi.org/10.1111/1475-6773.12073. · DOI
  80. Thompson D, Al-Lamee R, Foley M, Dehbi HM, Thom S, Davies JE, Francis DP, Patel P, Gupta P; ORBITA Investigators. Achieving optimal adherence to medical therapy by telehealth: findings from the ORBITA medication adherence sub-study. Pharmacol Res Perspect. 2021;9(1). https://doi.org/10.1002/prp2.710. PMID: 33570248; PMCID: PMC7876856. · DOI
  81. Vethe NT, Munkhaugen J, Andersen AM, Husebye E, Bergan S. A method for direct monitoring of atorvastatin adherence in cardiovascular disease prevention: quantification of the total exposure to parent drug and major metabolites using 2-channel chromatography and tandem mass spectrometry. Ther Drug Monit. 2019;41(1):19–28. https://doi.org/10.1097/FTD.0000000000000578. PMID: 30633723. · DOI
  82. Vethe NT, Husebye E, Andersen AM, Bergan S, Kristiansen O, Fagerland MW, Munkhaugen J. Monitoring simvastatin adherence in patients with coronary heart disease: a proof-of-concept study based on pharmacokinetic measurements in blood plasma. Ther Drug Monit. 2022;44(4):558–67. https://doi.org/10.1097/FTD.0000000000000992. PMID: 35482468. · DOI
  83. Virani SS, Woodard LD, Akeroyd JM, Ramsey DJ, Ballantyne CM, Petersen LA. Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Clin Cardiol. 2014;37(11):653–9. https://doi.org/10.1002/clc.22343. PMID:25324147;PMCID:PMC6649436. · DOI · Paper page
  84. Vitturi BK, Gagliardi RJ. The influence of statin withdrawal and adherence on stroke outcomes. Neurol Sci. 2021;42(6):2317–23. https://doi.org/10.1007/s10072-020-04790-y. PMID: 33037514. · DOI
  85. Volpp KG, Troxel AB, Mehta SJ, Norton L, Zhu J, Lim R, et al. Effect of electronic reminders, financial incentives, and social support on outcomes after myocardial infarction: the HeartStrong randomized clinical trial. JAMA Intern Med. 2017;177(8):1093–101. https://doi.org/10.1001/jamainternmed.2017.2449. PMID:28654972;PMCID:PMC5710431. · DOI · Paper page
  86. Wake M, Oh A, Onishi Y, Guelfucci F, Shimasaki Y, Teramoto T. Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan. Atherosclerosis. 2019;282:19–28. https://doi.org/10.1016/j.atherosclerosis.2018.12.026. PMID: 30669019. · DOI
  87. Wawruch M, Zatko D, Wimmer G Jr, Luha J, Wimmerova S, Matalova P, Kukumberg P, Murin J, Tesar T, Havelkova B, Shah R. Age-related differences in non-persistence with statin treatment in patients after a transient ischaemic attack. Clin Drug Investig. 2017;37(11):1047–54. https://doi.org/10.1007/s40261-017-0559-3. PMID: 28791591. · DOI
  88. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six-year follow-up study. Heart. 2002;88(3):229–33. https://doi.org/10.1136/heart.88.3.229. PMID:12181210;PMCID:PMC1767352. · DOI · Paper page
  89. Xie G, Sun Y, Myint PK, Patel A, Yang X, Li M, et al. Six-month adherence to statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes. Lipids Health Dis. 2017;16(1):155. https://doi.org/10.1186/s12944-017-0544-0. PMID:28810873;PMCID:PMC5558746. · DOI
  90. Xie G, Myint PK, Sun Y, Li X, Wu T, Gao RL, Wu Y. Associated factors for discontinuation of statin use one year after discharge in patients with acute coronary syndrome in China. BMJ Open. 2022;12(9):e056236. https://doi.org/10.1136/bmjopen-2021-056236. PMID:36104136;PMCID:PMC9476156. · DOI
  91. Yaglioglu H, Eryavuz Onmaz D, Abusoglu S, Erdem K, Sivrikaya A, Abusoglu G, Unlu A. New steps in acute coronary syndrome and antihyperlipidemic treatment: determination of statins and metabolites by liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 2022;36(8). https://doi.org/10.1002/bmc.5390. PMID: 35487588. · DOI
  92. Yu G, Zhang Y, Wang Y, Chang G, Tao H, Zhang D. Factors that contribute to poor adherence to statin therapy in coronary heart disease patients from Chongqing and measures to improve their therapeutic outcomes. Genes Dis. 2018;5(4):335–41. https://doi.org/10.1016/j.gendis.2018.01.001. PMID:30591935;PMCID:PMC6303681. · doi:10.1016/j.gendis.2018.01.001
  93. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74. https://doi.org/10.1097/00005650-198601000-00007. PMID: 3945130. · DOI · Paper page
  94. Risser J, Jacobson TA, Kripalani S. Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease. J Nurs Meas. 2007;15(3):203–19. https://doi.org/10.1891/106137407783095757. PMID: 18232619. · DOI · Paper page
  95. Carvalho ARS, Dantas RAS, Pelegrino FM, Corbi ISA. Adaptación y validación de una medida de adhesión a la terapia de anticoagulante oral. Rev Latino-Am Enfermagem. 2010;18(3):[8 pantallas]. · DOI
  96. Jang H, Mai XL, Lee G, Ahn JH, Rhee J, Truong KQ, et al. Simultaneous determination of statins in human urine by dilute-and-shoot-liquid chromatography-mass spectrometry. Mass Spectrom Lett. 2018;9(4):95–9. https://doi.org/10.5478/MSL.2018.9.4.95. · doi:10.5478/msl.2018.9.4.95
  97. Delgado AB, Lima ML. Contributing to the simultaneous validation of an additional measure of treatments. Psychol Health Dis. 2001;2:81–100.
  98. López San Román A. Adhesión al tratamiento, adherencia al tratamiento o cumplimiento del tratamiento? Rev Clin Esp. 2006;206(8):414. https://doi.org/10.1157/13090520. PMID: 16863639. · DOI
  99. Haynes RB. A critical review of the “determinants” of patient compliance with therapeutic regimens. In: Sackett DL, Haynes RD, editors. Compliance with therapeutic regimens. Baltimore: Johns Hopkins University Press; 1979. p. 24–40.
  100. Marinker M. From compliance to concordance: achieving shared goals in medicine taking. London: Royal Pharmaceutical Society; 1997.
  101. Snowden A, Martin C, Mathers B, Donell A. Concordance: a concept analysis. J Adv Nurs. 2014;70(1):46–59. https://doi.org/10.1111/jan.12147. · DOI
  102. Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51(8 Suppl 3). https://doi.org/10.1097/MLR.0b013e31829b1d2a. PMID: 23774515; PMCID: PMC3727405. · DOI · Paper page
  103. Márquez-Contreras E, López García-Ramos L, Martell-Claros N, Gil-Guillen VF, Márquez-Rivero S, Pérez-López E, et al. Validation of the electronic prescription as a method for measuring treatment adherence in hypertension. Patient Educ Couns. 2018;101(9):1654–60. https://doi.org/10.1016/j.pec.2018.04.009. PMID: 29731180. · DOI
  104. Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care. 2006;44(5):471–7. https://doi.org/10.1097/01.mlr.0000207817.32496.cb. PMID: 16641666. · DOI · Paper page
  105. Anghel LA, Farcaş AM, Oprean RN. Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. Patient Prefer Adherence. 2018;3(12):1151–66. https://doi.org/10.2147/PPA.S165101. PMID:30013327;PMCID:PMC6037147. · DOI
  106. Sayner R, Carpenter DM, Blalock SJ, Robin AL, Muir KW, Hartnett ME, et al. Accuracy of patient-reported adherence to glaucoma medications on a visual analog scale compared with electronic monitors. Clin Ther. 2015;37(9):1975–85. https://doi.org/10.1016/j.clinthera.2015.06.008. PMID:26164785;PMCID:PMC4568126. · DOI
  107. Venditti V, Bleve E, Morano S, Filardi T. Gender-related factors in medication adherence for metabolic and cardiovascular health. Metabolites. 2023;13(10):1087. https://doi.org/10.3390/metabo13101087. PMID:37887412;PMCID:PMC10609002. · DOI
  108. Chen SL, Lee WL, Liang T, et al. Factores asociados con las diferencias de género en la adherencia a la medicación: un estudio longitudinal. J Adv Nurs. 2014;70:2031–40. https://doi.org/10.1111/jan.12361. · DOI
  109. Barrett E, Paige E, Welsh J, et al. Differences between men and women in the use of preventive medications following a major cardiovascular event: Australian prospective cohort study. Prev Med Rep. 2021;22.https://doi.org/10.1016/j.pmedr.2021.101342. · DOI

Cited by

See all 11

Metadata

Authors
López-Pineda, A., Martinez-Muñoz, M., Nouni-García, R., Esquerdo-Arroyo, A., Carbonell-Soliva, Á., Ramirez-Familia, E., Tomás-Rodríguez, M. I., Quesada, J. A., C, C. C.-M., & Gil-Guillén, V. F.
Venue
Systematic Reviews
Published
2025-05-15
Volume
14
Issue
1
ISSN
2046-4053
Cited by
11
References
14
Language
en
Licence
Funders
  • Instituto de Salud Carlos III- RICAPPS (RD21/0016/0024)
  • Instituto de Salud Carlos III-Health Research Projects—Strategic Action in Health (PI20/01304)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.